secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kura Oncology, Inc. (KURA)
CIK:        0001422143
Form:       8-K
Filed at:   2024-05-02T23:59:59+00:00
Accession:  0000950170-24-052109
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kura Oncology Q1 net loss $49.5M, cash $527M; ziftomenib gets BTD for NPM1-mutant AML
--------------------------------------------------------------------------------

- Net loss of $49.5M in Q1 2024 vs $34.1M in Q1 2023; cash $527M provides runway into 2027.
- FDA granted Breakthrough Therapy Designation to ziftomenib for relapsed/refractory NPM1-mutant AML based on KOMET-001 data.
- Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment of 85 patients by mid-2024.
- Positive preliminary combo data: 100% CR rate in newly diagnosed with ziftomenib + 7+3; 53% ORR in R/R with venetoclax/azacitidine.
- First patient dosed with KO-2806 + cabozantinib in RCC; on track to dose with adagrasib in KRASG12C NSCLC by mid-2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422143/000095017024052109/0000950170-24-052109-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422143/000095017024052109/kura-20240502.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-052109

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer